The Relation Between Expression of P16, P53, CDK4/cyclinD1 and Prognosis in Breast Cancer Cells
TIAN Xing-song,ZHOU Wen-hong
DOI: https://doi.org/10.3969/j.issn.1005-6947.2005.04.006
2005-01-01
Abstract:Objective To study the expression levels of p16,p53,CDK4/cyclinD1 protein in breast cancer and their relationship to prognosis. Methods The expression of p16,p53,CDK4 and cyclinD1 in breast cancer tissues of 86 patients who did not receive preoperative chemotherapy were examined,and the ~relationship of their expression to clinicopathological data were analyzed.Results (1)p16,p53,CDK4:The positive expression of p16,p53 and CDK4 were significantly different in stages I and II infiltrating ductal carcinoma,but cyclin D showed no difference;their positive expression in lymph node negative and lymph node positive groups were significantly different;their positive expression for patients′age≤50 years and50 years showed no significat difference;there was significant difference of p53 expression between ER negative and ER positive groups,but p16,CDK4 and cyclin D expression showed no difference;p53 expression was ~significantly different in ER negative and PR positive groups,but the levels of the other proteins were not ~significantly different.(2)There were significant differences between the expression of p16 and p53(P~0.01 ),p16 and CDK4(P0.01),p16 and cyclinD1(P0.01).(3)Univariate survival analyses ~indicated that histological grade, axillary lymph node metastases, ER and PR status, ~expression of p16,CDK4 and cyclinD1 can affect the overall survival(P0.05). (4)~Multivariate analyses showed that only p53 and axillary lymph node metastases were prognostic ~factors for survival(P0.05).Conclusions The gene products of p16,p53,CDK4/~cyclinD1 play a significant role in the oncogenesis and development of cancer,and may be used as ~reference indicators to judge tumor invasion and metastasis,direction therapy and predict prognosis. p16 ~expression and axillary lymph node metastases may be in dependent prognostic indicators of ~postoperative survival in breast cancer patients. The combined use of the above markers may be helpful in making a better estimation of prognosis.